1Napolitano U, Imperato F, Mossa B, et al. The role of neoaju vant chemotherapy for squamous cell cervical cancer ( Ⅰ b- Ⅲ b) A long term randomized trials[J]. Eur J Gynecol Oncol, 2003,24 51-57.
2Abu-Surrah AS, Kettunen M. Platinum group antitumor chemistry:design and development of new anticaneer drugs complemen tary to cisplatin[J]. Curr Med Chem,2006,13(11):1337-1357.
1[1]Piver MS,Ghamande SA,Eltabbakh GH,et al.First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervix-a phase Ⅱ study.Gynecol Oncol,1999,75(3):334-337
2[2]Curtin JP,Blessing JA,Webster KD,et al.Paclitaxel,an active agent in nonsquamous carcinomas of the uterine cervix:a Gynecologic Oncology Group study.J Clin Oncol,2001,19(5):1275-1278
3[3]McGuire WP,Blessing JA,Moore D,et al.Paclitaxel has moderate activity in squamous cervix cancer:a Gynecologic Oncology Group study.J Clin Oncol,1996,14(3):792-795
4[4]Rose PG,Blessing JA,Gershenson DM,et al.Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix:a Gynecologic Oncology Group study.J Clin Oncol,1999,17(9):2676-2680
5[5]Dimopoulos MA,Papadimitriou CA,Sarris K,et al.Combination of ifosfamide,paclitaxel,and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix:a phase Ⅱ study of the Hellenic Cooperative Oncology Group.Gynecol Oncol,2002,85(3):476-482
6[6]Zanetta G,Fei F,Mangioni C.Chemotherapy with paclitaxel,ifosfamide,and cisplatin for the treatment of squamous cell cervical cancer:the experience of Monza.Semin Oncol,2000,27(1 Suppl 1:23-27
7[7]D'Agostino G,Distefano M,Greggi S,et al.Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin,paclitaxel and cisplatin.Cancer Chemother Pharmacol,2002,49(3):256-260
8[8]Cerrotta A,Gardan G,Cavina R,et al.Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix:a pilot study with intensification of dose.Eur J Gynaecol Oncol,2002,23(2:115-119
9[9]Pignata S,Frezza P,Tramontana S,et al.Phase Ⅰ study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri.Ann Oncol,2000,11(4):455-459
10[10]Ball HG,Blessing JA,Lentz SS,et al.A phase Ⅱ trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium:a Gynecologic Oncology Group study.Gynecol Oncol,1996,62(2:278-281
1Gold MA, Tian C, Whitney CW, et al. Surgical versus radiographic determination of para-aortic lymph node metastases before chemoradiation for locally advanced cervical carcinoma: a Gynecologic Oncology Group Study. Cancer, 2008,112 (9) : 1954- 1963.
2S ve P, Dumontet C. Class In beta tubulin expression in nonsmall cell lung cancer. Rev Mal Respir, 2010, 27(4) : 383-386.
3Izutsu N, Maesawa C, Shibazaki M, et al. Epigenetic modification is involved in aberrant expression of class llI beta-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol, 2008,32(6) : 1227-1235.
4Loizzi V, Cormio G, Vicino M, et al. Neoadjuvant chemotherapy: an alternative option of treatment for locally advanced cervical cancer. Gynecol Obstet Invest, 2008,65(2) :96-103.
5Lee JM, Lee KB, Nam JH, et al. Prognostic factors in FIGO stage I B- II A small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncal, 2008,19(2) : 321-326.
6S ve P, Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol, 2008,9 (2):168-175.
